Rare Disease Biopharma M&A: Navigating the 2028 Patent Cliff

The pharmaceutical industry faces an unprecedented loss-of-exclusivity wave centered around 2028. The most prominent pressure point is Merck & Co., where Keytruda—accounting for over 55% of the company's total pharmaceutical sales across dozens of indications—begins confronting patent expiries in 2028. Similar revenue cliffs across large-cap oncology, immunology, and cardiovascular portfolios mean major pharmaceutical operators must acquire durable, high-margin revenue streams to replace dozens of billions of dollars in expiring cash flows.

In this environment, rare disease biotechs are the most economically attractive acquisition targets. Unlike primary care drugs, orphan therapies benefit from long regulatory exclusivity windows, high gross margins, defensible pricing power, sticky patient populations, and minimal commercial overhead (requiring small, targeted sales forces rather than multi-thousand-person commercial armies).

However, big pharma acquirers cannot afford to absorb speculative, dilutive science experiments that drag down near-term return on invested capital (ROIC). The acquirable targets must possess clean balance sheets, established cash reserves or self-funding cash flow, and commercially de-risked or approved assets.

---

1. Catalyst Pharmaceuticals (NASDAQ: CPRX) — The Cash-Flow-Accretive Commercial Platform

Catalyst represents the rarest asset class in small-cap specialty biopharma: a completely self-funded, cash-generative orphan drug commercializer with zero long-term debt and expanding operating margins.

• Commercial Moat: Catalyst’s flagship revenue generator is Firdapse (amifampridine), the only FDA-approved therapy in the United States for Lambert-Eaton Myasthenic Syndrome (LEMS). In August 2025, Firdapse was formally written into the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines as standard of care, anchoring physician adoption and standardizing insurance reimbursement.
• Intellectual Property Protection: Catalyst has methodically cleared its patent overhangs. After prevailing in patent litigation and appeals against generic filers (including Teva Pharmaceuticals, Lupin, and Inventia Healthcare), its settlements have secured Firdapse’s exclusivity through February 2035. The remaining challenge (with generic manufacturer Hetero USA) represents the final legal clearing event.
• Balance Sheet & Acquirer Fit: Operating with no debt, robust positive cash flows, and a growing liquidity cushion, Catalyst acquires de-risked assets from capital-constrained developers and scales them through its dedicated patient-identification and distribution infrastructure. For a large pharmaceutical company facing an immediate top-line hole in 2028, Catalyst provides an instantly accretive, high-margin bolt-on requiring zero restructuring or capital injection.

---

2. Ultragenyx Pharmaceutical (NASDAQ: RARE) — The Multi-Asset Late-Stage Franchise

For an acquirer looking to absorb an entire late-stage rare-disease engine rather than a single-product company, Ultragenyx represents an established commercial and late-stage clinical platform.

• Commercial Diversification: As reported in its Form 10-K for the fiscal year ended December 31, 2025, Ultragenyx already markets four approved therapies:
  • Crysvita (burosumab) for X-linked hypophosphatemia and tumor-induced osteomalacia.
  • Mepsevii (vestronidase alfa) for mucopolysaccharidosis VII (MPS VII / Sly syndrome).
  • Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders (LC-FAOD).
  • Evkeeza (evinacumab) outside the U.S. for homozygous familial hypercholesterolemia (HoFH).
• Late-Stage Pipeline De-Risking: Beyond its approved base, Ultragenyx’s 2025 Form 10-K outlines advanced clinical programs targeting areas of significant unmet need with defined biology:
  • UX111 (AAV9): Gene therapy candidate in late-stage development for Sanfilippo syndrome type A (MPS IIIA).
  • DTX401 (AAV8): Gene therapy candidate for glycogen storage disease type Ia (GSDIa).
  • GTX-102: An antisense oligonucleotide (ASO) in clinical evaluation for Angelman syndrome.
  • UX701 & UX143: Clinical programs targeting Wilson disease and osteogenesis imperfecta (OI), respectively.
• The Strategic Fit: In Note 1 and the Cash Flow statements of its 2025 Form 10-K, Ultragenyx notes that it has sustained operating losses and relied on equity offerings, royalty sales, and collaboration capital to fund R&D. For a large pharmaceutical company, Ultragenyx’s structural loss is purely an artifact of clinical R&D overhead; under a large-pharma umbrella, overlapping development and administrative costs could be rationalized immediately, allowing the commercial and late-stage rare-disease portfolio to deliver substantial operational leverage.

---

3. Moderna (NASDAQ: MRNA) — Intracellular Rare Disease Pipeline

While broad market consensus views Moderna through the lens of respiratory vaccines and its Phase 3 oncology collaboration with Merck (designed specifically to help Merck mitigate its post-2028 Keytruda cliff), Moderna has leveraged its multi-billion-dollar pandemic cash hoard to fully fund a wholly owned rare-disease portfolio.

• Clinical Registrational Assets: As disclosed in its Form 10-K for the fiscal year ended December 31, 2025, Moderna is advancing two pivotal intracellular enzyme replacement mRNA therapies targeting rare metabolic disorders:
  • mRNA-3927 (Propionic Acidemia): Designed to restore functional propionyl-CoA carboxylase (PCC) enzyme activity in the liver. At the International Congress of Inborn Errors of Metabolism (ICIEM) in September 2025, Moderna reported that its global Phase 1/2 trial demonstrated a sustained reduction in life-threatening metabolic decompensation events (MDEs), with target enrollment reached in its registrational study.
  • mRNA-3705 (Methylmalonic Acidemia): Targeting methylmalonyl-CoA mutase (MUT) deficiency, which carries a 40% to 50% mortality rate in early childhood and currently lacks an approved root-cause therapy.
• Financial Insulation: Unlike small-cap clinical biotechs that face solvency risks while conducting registrational rare-disease trials, Moderna's pipeline is entirely self-funded from its balance sheet. If big pharma acquirers seek to buy into validated intracellular protein-replacement modalities ahead of 2028, Moderna’s late-stage rare metabolic assets are prime targets for carve-out licensing, co-commercialization pacts, or outright franchise acquisitions.

---

The Fundamental Evaluation Checklist for Investors

When underwriting rare disease biotechs as potential beneficiaries of the 2028 patent cliff, avoid early-stage science and screen against these strict financial and operational hurdles:

1. Exclusivity Horizon Past 2033–2035: The acquisition must solve the acquirer's post-2028 cliff, not recreate it in 2030. Intellectual property must be backed by unassailable composition-of-matter patents or litigated court settlements (as with Catalyst’s 2035 window).
2. Phase 2 Proof-of-Concept or Direct Commercial Cash Flow: Preclinical pipelines offer zero margin of safety. Potential targets must have clear biomarker validation, registrational enrollment (e.g., Moderna's mRNA-3927), or active in-market billing (e.g., Ultragenyx and Catalyst).
3. No Terminal Dilution Risk: Biotechs that must continuously raise equity at cyclically depressed valuations destroy per-share value long before a buyout offer arrives. Prioritize companies that fund their own operations through commercial cash generation or massive balance-sheet reserves.